Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. - Wikidata - awgldk - TriplyDB

Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.

Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.

http://www.wikidata.org/entity/Q34886764

about

Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.Breast cancer brain metastases: biology and new clinical perspectives Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context.Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Central nervous system metastasis from breast cancer.Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series Unsanctifying the sanctuary: challenges and opportunities with brain metastases.Understanding Heterogeneity and Permeability of Brain Metastases in Murine Models of HER2-Positive Breast Cancer Through Magnetic Resonance Imaging: Implications for Detection and Therapy.The use of stereotactic radiosurgery for brain metastases from breast cancer: who benefits most?Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio.A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience.Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.Evaluating Changes to Blood-Brain Barrier Integrity in Brain Metastasis over Time and after Radiation Treatment.Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.The future of targeted therapies for brain metastases.Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance.Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.Updates in the management of brain metastases.Advances in drug delivery to high grade gliomas.Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors.The Microenvironmental Landscape of Brain Tumors.Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.Activity of T-DM1 in Her2-positive breast cancer brain metastases.Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer.Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.Translational gap in ongoing clinical trials for glioma.Imaging and clinical end points in brain metastases trials.Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review.Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatment.Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.

P2860

Q26751008-903432C3-33A0-416F-8874-C5E82C68DDF5 Q26778701-22C97EA6-BC15-491B-8F12-A9294F45ECDA Q28078998-DBF5008C-45DF-4A27-A3A9-3E03FA0158C9 Q30238959-5906919A-02C5-4425-AA53-DC439F532F7E Q30239901-E43F1A2F-84DB-4988-9AB6-E6885EAE24D0 Q34960132-9D1503CD-F50D-4CF5-B064-0310A11602EB Q35067584-FFFF1F5F-B3B1-4CE1-A04A-F7D55CA52AB3 Q35582767-1D6333AF-4D69-4785-9906-D8BF9489A9C8 Q35647947-92BD1A3E-0611-4669-8800-302B414C0E1C Q35788631-CABCD682-BDEB-4E62-AFB7-5EFD101F9B9A Q35804288-B781EE69-AD38-4684-A28D-C8EC7800E6C8 Q35828015-7E1E247C-65AF-45CE-AAF3-F0CE9D8880D7 Q35904011-1BC1C557-4957-4D5E-9010-8A091A2B2AC6 Q36452287-3BCF9A10-CCAF-4CD9-A3A5-54650CEA81D7 Q36600202-0588F75B-F90F-4DC9-B222-C23D0DD81211 Q37004561-815329D5-9F71-495B-B4E7-39A01DC21B78 Q37350784-DF467E14-B4EE-4E11-9B35-9CAF382E40D5 Q37694756-A4318ECC-A558-4E22-B595-854BE2BEF613 Q38564085-BD336B31-B145-4C2F-86E5-08D5111B0971 Q38688750-56458CBF-2F7B-4F11-A106-FCA442E59B98 Q38792519-6AD748B9-11EA-4461-8AAC-823691476C2E Q38816270-DC86F648-64E0-4227-8A26-FC434F850ABF Q38827063-B387CFFA-2F94-4174-850C-F41D2E5C7FA0 Q38887451-C968EF3A-A331-4484-8903-846997CC76CE Q38917630-7108F6DA-F6F3-4513-BA45-B8150571D039 Q38975455-92FE84FA-6B47-4BA8-8B15-7587F7983B10 Q39178065-0A8D230C-520D-4F74-B18E-E53BA40F5E63 Q39721426-95164108-E028-4055-AE1E-D97372DCB801 Q39775271-217DB1A4-5244-40C2-AAF8-E1F3BCEF1531 Q41455800-0719BC2E-105D-4CD5-B8F7-6F056E9A3A65 Q44152087-1E0D5E25-FED7-42AB-88D9-8989EDC55521 Q47549277-369C62F1-964F-4581-A28B-B68E2754F717 Q47839509-3ADF9553-F1FF-4685-B9F2-9386A231E277 Q48002716-61BF843F-6D3E-44DB-86DA-15B637F39C25 Q48031513-D24AF514-5A66-4925-90B4-6DADFFD576C8 Q48162978-BC6336D0-6C42-49D8-9ACA-F6B652A66E4D Q48713634-F4A1CC94-4F3F-4861-8853-6E6DF53313A6 Q50043843-5DF73A5C-836F-4B0A-95E6-255CBE2F6856 Q52578959-1BF19781-5F83-4D72-B382-6FBA8D0D048F Q54118354-9CBE0AB7-AB73-420F-90CB-D61FA6374E0A

P2860

Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.

http://www.wikidata.org/entity/Q34886764

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Capecitabine and lapatinib upt ...... patients: a prospective study.

@ast

Capecitabine and lapatinib upt ...... patients: a prospective study.

@en

Capecitabine and lapatinib upt ...... patients: a prospective study.

@nl

type

label

Capecitabine and lapatinib upt ...... patients: a prospective study.

@ast

Capecitabine and lapatinib upt ...... patients: a prospective study.

@en

Capecitabine and lapatinib upt ...... patients: a prospective study.

@nl

prefLabel

Capecitabine and lapatinib upt ...... patients: a prospective study.

@ast

Capecitabine and lapatinib upt ...... patients: a prospective study.

@en

Capecitabine and lapatinib upt ...... patients: a prospective study.

@nl

P1433

Q34886764-AC8720FA-888C-4BC8-BD99-A12A5B84C93A

P1476

Q34886764-26F9A88D-8901-4B6B-A19F-EC82FC1318D2

P2093

Q34886764-138F1614-C165-4AAA-B9B4-D47F5AD80DC7

Q34886764-1AFB015B-A420-4701-BAF1-CBFBDF86719B

Q34886764-4F97D6C4-93B3-4DA3-88A1-3A9A1E054D5E

Q34886764-72C99077-394B-4847-A451-307EB20BEF69

Q34886764-799B71AF-19FD-4972-B968-64DDF2524EC0

Q34886764-7B6D43FC-5577-436B-B535-3F32EB78012B

Q34886764-7DD233DD-FCFB-457F-9594-DD0447402134

Q34886764-87D73064-7782-4D98-8344-EDD789C40231

Q34886764-AA87541F-C5E5-49EE-9EAC-20A3531151F2

Q34886764-E7F23D22-F901-4090-AF5F-1FDAC249D93F

P2860

Q34886764-14B9F8F9-8B0D-4DE4-A3B9-B8443B509D98

Q34886764-175DF65D-8CC4-41FB-87B9-E239CB2F4D52

Q34886764-1C8BB972-CC95-4C54-89CB-6AEF92B747F4

Q34886764-23158100-9F75-4DC2-86BC-FB81D1FD8FCD

Q34886764-26B7F40F-9A6D-47B6-A40C-F01160F192E2

Q34886764-29FB9346-783E-49BA-8188-7D55547A935D

Q34886764-4ADA6E31-E761-4998-88C0-6D21540D6355

Q34886764-623C406F-C964-4064-91B3-A0A294A07FA5

Q34886764-62EF00DA-6E3D-47C8-8B95-C855E775442F

Q34886764-6A37BE04-8B32-459C-899D-E4AFB86445D7

P304

Q34886764-4ABB8FE6-908D-416F-9D3E-60E60BC2CBB2

P31

Q34886764-64F18F9F-E299-44FE-A241-6CEE18A1E1E0

P356

Q34886764-67539519-FB7C-4D92-A139-87E2DE22E071

P433

Q34886764-1FC3A2AA-FEA2-4EB8-AEAC-E600BFEC1303

P478

Q34886764-6AB566BE-499C-448D-AB01-1F5611056A71

P50

Q34886764-D810FD83-0E8A-4F57-8397-39744D82471B

P577

Q34886764-D0A49FE3-DF83-4E48-A30A-7CFBB68286C1

P698

Q34886764-AD017A56-4917-44AE-B5F3-B9CD9534D052

P921

Q34886764-4627E8D1-62CA-4097-9C26-7B5D7369C348

Q34886764-E5BB76C1-0A9F-483C-A11B-C5CFC31117C7

P932

Q34886764-707FDF78-7AAD-41FF-9C21-05D8574428F9

P356

P1433

P1476

Capecitabine and lapatinib upt ...... patients: a prospective study.

@en

P2093

Ahkeem Simmons

http://www.w3.org/2001/XMLSchema#string

Aki Morikawa

http://www.w3.org/2001/XMLSchema#string

Andrew D Seidman

http://www.w3.org/2001/XMLSchema#string

Conleth G Murphy

http://www.w3.org/2001/XMLSchema#string

David M Peereboom

http://www.w3.org/2001/XMLSchema#string

Helen R Thorsheim

http://www.w3.org/2001/XMLSchema#string

Patricia S Steeg

http://www.w3.org/2001/XMLSchema#string

Paul R Lockman

http://www.w3.org/2001/XMLSchema#string

Quentin R Smith

http://www.w3.org/2001/XMLSchema#string

Rajiv Balyan

http://www.w3.org/2001/XMLSchema#string

P2860

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.

Clinical pharmacokinetics of capecitabine.

Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.

The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.

CNS metastases in breast cancer.

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.

P304

289-295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOU141

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25015089

http://www.w3.org/2001/XMLSchema#string

P921

P932

4288517

http://www.w3.org/2001/XMLSchema#string